King Faisal Specialist Hospital and Research Centre (KFSH) is a leader in clinical research in Saudi Arabia, having conducted nearly half of all registered clinical trials in the nation during the first half of 2025. Backed by a dedicated and skilled workforce, KFSH’s clinical trials span a variety of medical fields, creating opportunities for patients to access cutting-edge therapeutic options and contributing vital evidence to the healthcare system.
Innovative Clinical Trials Framework
KFSH established its centralized Clinical Trials service in 2020 to streamline the management of studies conducted by hospital researchers and clinicians. This service is integral to administering feasibility assessments, trial operations, and ensuring compliance with safety and regulatory guidelines. The team comprises experienced investigators, research nurses, pharmacists, and coordinators focused on fostering effective collaboration among patients, sponsors, and international research partners.
During the first half of 2025, KFSH managed 104 active trials and initiated 80 new studies across diverse medical conditions including cancer, cardiovascular diseases, autoimmune disorders, dermatology, and metabolic disorders. This wide-ranging portfolio allows physicians to offer patients with complex health issues novel treatment options, while concurrently generating evidence essential for addressing the healthcare needs of Saudi Arabia.
Transforming Patient Care with Cutting-edge Research
A notable highlight from KFSH’s clinical trials is the groundbreaking Phase I trial involving genetically engineered CAR-T cells tailored for treating relapsed acute lymphoblastic leukemia. This innovative project underscores the synergy between local scientific expertise, advanced biomanufacturing, and specialized clinical care, all contributing to a seamless translational pathway for patient care.
KFSH’s robust research model not only positions the hospital to advance its internal capabilities but also enhances Saudi Arabia’s role in international clinical research collaborations. With centralized trial management and a strong foundation in research governance, KFSH is well-equipped to meet the demands of multinational studies while upholding rigorous standards for ethics, patient safety, and data integrity.
Driving Innovation through Responsible Clinical Trials
While scientific advancements in areas like artificial intelligence, biotechnology, and genomics show promise, they must be assessed through an efficient clinical trials framework. KFSH is committed to showcasing the importance of responsible innovation testing at the upcoming C3 US NYC Davos of Healthcare™ Summit 2026. This commitment emphasizes the hospital’s role in generating the evidence necessary for the adoption of new treatments, ultimately improving patient care.
KFSH’s dedication to excellence is further validated by its recognition as the highest-ranked hospital in the Middle East and Africa and 12th globally among academic medical centers for 2026. The hospital has also been distinguished as the most valuable healthcare brand in the region, gaining accolades from prominent organizations like Brand Finance and Newsweek.
In summary, King Faisal Specialist Hospital and Research Centre stands at the forefront of clinical research in Saudi Arabia, driving innovation and providing essential therapeutic options to patients. Through its centralized clinical trials service, KFSH is not only enhancing patient care but also contributing significantly to global healthcare advancements.